Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 11

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

A Novel p53 Mutant Found in Iatrogenic Urothelial Cancers Is Dysfunctional and Can Be Rescued by a Second-site Global Suppressor Mutation

Odell, Adam F., Odell, Luke R., Askham, Jon M., Alogheli, Hiba, Ponnambalam, Sreenivasan, Hollstein, Monica·2013·Journal of Biological Chemistry
DOI 10.1074/jbc.m112.443168
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m112.443168

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 29

  1. Oren, 2010, Mutant p53 gain-of-function in cancer, Cold Spring Harb. Perspect. Biol, 2, a001107, 10.1101/cshperspect.a001107 · DOI · Paper page
  2. Vogelstein, 2000, Surfing the p53 Network, Nature, 408, 307, 10.1038/35042675 · DOI · Paper page
  3. Freed-Pastor, 2012, Mutant p53: one name, many proteins, Genes Dev, 26, 1268, 10.1101/gad.190678.112 · DOI · Paper page
  4. Kato, 2003, Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis, Proc. Natl. Acad. Sci. U.S.A, 100, 8424, 10.1073/pnas.1431692100 · DOI · Paper page
  5. Petitjean, 2007, Impact of mutant p53 functional properties on TP53 mutation patterns and tumour phenotype: Lessons from recent developments in the IARC TP53 database, Human Mutation, 28, 622, 10.1002/humu.20495 · DOI · Paper page
  6. Greenman, 2007, Patterns of somatic mutation in human cancer genomes, Nature, 446, 153, 10.1038/nature05610 · DOI · Paper page
  7. Chen, 2012, Aristolochic acid-associated urothelial cancer in Taiwan, Proc. Natl. Acad. Sci. U.S.A, 109, 8241, 10.1073/pnas.1119920109 · DOI · Paper page
  8. Hollstein, 2013, Analysis of TP53 mutation spectra reveals the fingerprint of the potent carcinogen, aristolochic acid, Mutat. Res, 10.1016/j.mrrev.2013.02.003 · DOI
  9. Olivier, 2012, Upper urinary tract urothelial cancers: where it's A:T, Nat. Rev. Cancer, 12, 503, 10.1038/nrc3311 · doi:10.1038/nrc3311
  10. Schetter, 2012, Tumor suppressor p53 (TP53) at the crossroads of the exposome and the cancer genome, Proc. Natl. Acad. Sci. U.S.A, 109, 7955, 10.1073/pnas.1205457109 · DOI
  11. Wei, 2012, Efficient introduction of specific p53 mutations into mouse embryonic fibroblasts and embryonic stem cells, Nat. Protoc, 7, 1145, 10.1038/nprot.2012.042 · DOI
  12. Wei, 2011, Rapid derivation of genetically related mutants from embryonic cells harbouring a recombinase-specific Trp53 platform, Cell Cycle, 10, 1261, 10.4161/cc.10.8.15303 · doi:10.4161/cc.10.8.15303
  13. Mathew, 2008, Immortalized mouse epithelial cell models to study the role of apoptosis in cancer, Methods Enzymol, 446, 77, 10.1016/S0076-6879(08)01605-4 · DOI
  14. Whibley, 2010, Wild-type and Hupki (human p53 knock-in) murine embryonic fibroblatsts: p53/ARF pathway disruption in spontaneous escape from senescence, J. Biol. Chem, 285, 11326, 10.1074/jbc.M109.064444 · DOI
  15. Joerger, 2010, The tumour suppressor p53: from structures to drug discovery, Cold Spring Harb. Perspect. Biol, 2, a000919, 10.1101/cshperspect.a000919 · DOI · Paper page
  16. Luo, 2001, Knock-in Hupki mice with a humanised p53 gene develop normally and show wild-type p53 responses to DNA damaging agents, Oncogene, 20, 320, 10.1038/sj.onc.1204080 · DOI
  17. Song, 2007, P53 gain-of-function cancer mutants induce genetic instability by inactivating ATM, Nat. Cell Biol, 9, 573, 10.1038/ncb1571 · DOI · Paper page
  18. Baroni, 2004, A global suppressor motif for p53 cancer mutants, Proc. Natl. Acad. Sci. U.S.A, 101, 4930, 10.1073/pnas.0401162101 · DOI
  19. Otsuka, 2007, The screening of the second-site suppressor mutations of the common p53 mutants, Int. J. Cancer, 121, 559, 10.1002/ijc.22724 · DOI · Paper page
  20. Danziger, 2009, Predicting positive p53 cancer rescue regions using Most Informative Positive (MIP) active learning, PLoS Comput. Biol, 5, e1000498, 10.1371/journal.pcbi.1000498 · DOI
  21. Merabet, 2010, Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for Restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights, Biochem. J, 427, 225, 10.1042/BJ20091888 · DOI
  22. Nedelko, 2009, TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours, Int. J. Cancer, 124, 987, 10.1002/ijc.24006 · DOI
  23. Liu, 2004, Human tumour p53 mutations are selected for in mouse embryonic fibroblasts harbouring a humanized p53 gene, Proc. Natl. Acad. Sci. U.S.A, 101, 2963, 10.1073/pnas.0308607101 · DOI
  24. Besaratinia, 2010, Applications of the human p53 knock-in (Hupki) mouse model for human carcinogen testing, FASEB J, 24, 2612, 10.1096/fj.10-157263 · DOI
  25. Olivier, 2010, TP53 mutations in human cancers: origins, consequences, and clinical use, Cold Spring Harb. Perspect. Biol, 2, a001008, 10.1101/cshperspect.a001008 · DOI · Paper page
  26. Nikolova, 1998, Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability, Proc. Natl. Acad. Sci. U.S.A, 95, 14675, 10.1073/pnas.95.25.14675 · DOI · Paper page
  27. Joerger, 2006, Structural basis for understanding oncogenic p53 mutations and designing rescue drugs, Proc. Natl. Acad. Sci. U.S.A, 103, 15056, 10.1073/pnas.0607286103 · DOI · Paper page
  28. Lai, 2010, Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk, J Natl. Cancer Inst, 102, 179, 10.1093/jnci/djp467 · DOI · Paper page
  29. Hussain, 2007, TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer, Oncogene, 26, 2166, 10.1038/sj.onc.1210279 · DOI · Paper page

Cited by

See all 11

Metadata

Authors
Odell, A. F., Odell, L. R., Askham, J. M., Alogheli, H., Ponnambalam, S., & Hollstein, M.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2013-06
Volume
288
Issue
23
Pages
16704-16714
ISSN
0021-9258
DOI
10.1074/jbc.m112.443168
Cited by
11
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Novel p53 Mutant Found in Iatrogenic Urothelial Cancers Is Dysfunctional and Can Be Rescued by a Second-site Global Suppressor Mutation. https://app.cochat.ai/papers/10.1074/jbc.m112.443168
The paper
Odell, A. F., Odell, L. R., Askham, J. M., Alogheli, H., Ponnambalam, S., & Hollstein, M. (2013). A Novel p53 Mutant Found in Iatrogenic Urothelial Cancers Is Dysfunctional and Can Be Rescued by a Second-site Global Suppressor Mutation. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.m112.443168

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.